WO2007024744A3 - Composes de carboxamide heterocycliques en tant qu'agents pharmaceutiques - Google Patents

Composes de carboxamide heterocycliques en tant qu'agents pharmaceutiques Download PDF

Info

Publication number
WO2007024744A3
WO2007024744A3 PCT/US2006/032459 US2006032459W WO2007024744A3 WO 2007024744 A3 WO2007024744 A3 WO 2007024744A3 US 2006032459 W US2006032459 W US 2006032459W WO 2007024744 A3 WO2007024744 A3 WO 2007024744A3
Authority
WO
WIPO (PCT)
Prior art keywords
nuclear receptor
receptor ligands
carboxamide compounds
steroid nuclear
heterocyclic carboxamide
Prior art date
Application number
PCT/US2006/032459
Other languages
English (en)
Other versions
WO2007024744A2 (fr
Inventor
Brenton T Flatt
Xiao Hui Gu
Richard Martin
Raju Mohan
Brett Murphy
Michael Charles Nyman
William C Stevens
Tie Lin Wang
Lynne Canne Bannen
Original Assignee
Exelixis Inc
Brenton T Flatt
Xiao Hui Gu
Richard Martin
Raju Mohan
Brett Murphy
Michael Charles Nyman
William C Stevens
Tie Lin Wang
Lynne Canne Bannen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exelixis Inc, Brenton T Flatt, Xiao Hui Gu, Richard Martin, Raju Mohan, Brett Murphy, Michael Charles Nyman, William C Stevens, Tie Lin Wang, Lynne Canne Bannen filed Critical Exelixis Inc
Publication of WO2007024744A2 publication Critical patent/WO2007024744A2/fr
Publication of WO2007024744A3 publication Critical patent/WO2007024744A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

La présente invention concerne des composés de carboxamide hétérocycliques qui sont utiles pour moduler l'activité de récepteurs nucléaires stéroïdes. L'invention a également pour objet des compositions pharmaceutiques contenant ces composés, des procédés pour utiliser ces composés, et des procédés pour les préparer.
PCT/US2006/032459 2005-08-21 2006-08-18 Composes de carboxamide heterocycliques en tant qu'agents pharmaceutiques WO2007024744A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US71027305P 2005-08-21 2005-08-21
US60/710,273 2005-08-21

Publications (2)

Publication Number Publication Date
WO2007024744A2 WO2007024744A2 (fr) 2007-03-01
WO2007024744A3 true WO2007024744A3 (fr) 2007-06-07

Family

ID=37684876

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/032459 WO2007024744A2 (fr) 2005-08-21 2006-08-18 Composes de carboxamide heterocycliques en tant qu'agents pharmaceutiques

Country Status (1)

Country Link
WO (1) WO2007024744A2 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2185506A1 (fr) * 2007-08-22 2010-05-19 Allergan, Inc. Composés pyrroliques ayant une activité agoniste de récepteur de sphingosine-1-phosphate ou une activité biologique antagoniste
JO3215B1 (ar) 2012-08-09 2018-03-08 Phenex Pharmaceuticals Ag حلقات غير متجانسة بها 5 ذرات تحتوي على النيتروجين بها استبدال بكربوكساميد أو سلفوناميد كمعدلات لمستقبل نووي غير محمي RORy
AU2014204978A1 (en) 2013-01-10 2015-08-20 Grünenthal GmbH Pyrazolyl-based carboxamides I as CRAC channel inhibitors
EA201500737A1 (ru) 2013-01-10 2016-04-29 Грюненталь Гмбх Пиразолилкарбоксамиды ii в качестве ингибиторов crac каналов
WO2015197187A1 (fr) 2014-06-24 2015-12-30 Grünenthal GmbH Carboxamides à base de pyrazolyle v
MX2020003671A (es) 2017-10-06 2020-08-03 Forma Therapeutics Inc Inhibicion de peptidasa especifica de ubiquitina 30.
LT3860989T (lt) 2018-10-05 2023-06-12 Forma Therapeutics, Inc. Sulieti pirolinai, kurie veikia kaip ubikvitinui specifinės proteazės 30 (ups30) inhibitoriai
JP2023519892A (ja) 2020-03-27 2023-05-15 ランドス バイオファーマ インコーポレイテッド Ｐｌｘｄｃ２リガンド
WO2024059524A1 (fr) * 2022-09-12 2024-03-21 Hotspot Therapeutics, Inc. Composés de pyrazolylcarboxamide et leur utilisation en thérapie

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003007887A2 (fr) * 2001-07-20 2003-01-30 Merck & Co., Inc. Imidazoles substitues servant de modulateurs de recepteurs de cannabinoides
WO2003027076A2 (fr) * 2001-09-21 2003-04-03 Solvay Pharmaceuticals B.V. Derives de 1h-imidazole ayant une activite antagoniste de cb1
WO2003063781A2 (fr) * 2002-01-29 2003-08-07 Merck & Co., Inc. Imidazoles substitues en tant que modulateurs du recepteur cannabinoide
WO2004085419A1 (fr) * 2003-03-24 2004-10-07 Basf Aktiengesellschaft Anilide d'acide carboxylique trifluoromethylthiophene et son utilisation en tant que fongicide
WO2006076202A1 (fr) * 2005-01-10 2006-07-20 Exelixis, Inc. Composes carboxamides heterocycliques utilises ent ant qu'agents pharmaceutiques

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003007887A2 (fr) * 2001-07-20 2003-01-30 Merck & Co., Inc. Imidazoles substitues servant de modulateurs de recepteurs de cannabinoides
WO2003027076A2 (fr) * 2001-09-21 2003-04-03 Solvay Pharmaceuticals B.V. Derives de 1h-imidazole ayant une activite antagoniste de cb1
WO2003063781A2 (fr) * 2002-01-29 2003-08-07 Merck & Co., Inc. Imidazoles substitues en tant que modulateurs du recepteur cannabinoide
WO2004085419A1 (fr) * 2003-03-24 2004-10-07 Basf Aktiengesellschaft Anilide d'acide carboxylique trifluoromethylthiophene et son utilisation en tant que fongicide
WO2006076202A1 (fr) * 2005-01-10 2006-07-20 Exelixis, Inc. Composes carboxamides heterocycliques utilises ent ant qu'agents pharmaceutiques

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
ANTOLINI M ET AL: "Analogues of 4,5-bis(3,5-dichlorophenyl)-2- trifluoromethyl-1H-imidazole as potential antibacterial agents", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 9, no. 7, 5 April 1999 (1999-04-05), pages 1023 - 1028, XP004162577 *
CAPUANO L ET AL: "Chemie der 2,3-Dihydro-2,3-diiminofurane", LIEBIGS ANNALEN DER CHEMIE, vol. 12, 1982, pages 2178 - 2188, XP002188095 *
DYCK B ET AL: "Potent imidazole and triazole CB1 receptor antagonists related to SR141716", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 14, no. 5, 8 March 2004 (2004-03-08), pages 1151 - 1154, XP001197288 *
GOMPPER R ET AL: "Umsetzung von Imidazolen mit Isocyanaten", CHEMISCHE BERICHTE, vol. 92, no. 3, 12 March 1959 (1959-03-12), pages 550 - 563, XP002378856 *
KUDO N ET AL: "Synthesis and herbicidal activity of 1,5-diarylpyrazole derivatives", CHEMICAL AND PHARMACEUTICAL BULLETIN, vol. 47, no. 6, 1999, pages 857 - 868, XP001026111 *
LAN R ET AL: "Structure-activity relationships of pyrazole derivatives as cannabinoid receptor antagonists", JOURNAL OF MEDICINAL CHEMISTRY, vol. 42, no. 4, 1999, pages 769 - 776, XP002145465 *
PAPADOPOULOS E P: "Reactions of imidazoles with isocyanates at elevated temperature", JOURNAL OF ORGANIC CHEMISTRY, vol. 42, no. 24, 25 November 1977 (1977-11-25), pages 3925 - 3929, XP002378857 *
SHIM J-Y ET AL: "Molecular interaction of the antagonist N-(piperidin-1-yl)- 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide with the CB1 cannabinoid receptor", JOURNAL OF MEDICINAL CHEMISTRY, vol. 45, no. 7, March 2002 (2002-03-01), pages 1447 - 1459, XP002968557 *
TRANBERG C E ET AL: "2-Amino-3-aroyl-4,5-alkylthiophenes: agonist allosteric enhancers at human A1 adenosine receptors", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 45, no. 2, 19 December 2002 (2002-12-19), pages 382 - 389, XP002378855, ISSN: 0022-2623 *
UEDA T ET AL: "A novel ring transformation of 5-acylaminouracils and 5-acylamino-pyrimidin-4(3H)-ones into imidazoles", TETRAHEDRON LETTERS, vol. 29, no. 36, 1988, pages 4607 - 4610, XP001038533 *

Also Published As

Publication number Publication date
WO2007024744A2 (fr) 2007-03-01

Similar Documents

Publication Publication Date Title
WO2007024744A3 (fr) Composes de carboxamide heterocycliques en tant qu'agents pharmaceutiques
TW200607798A (en) Progesterone receptor modulators comprising pyrrole-oxindole derivatives and uses thereof
WO2007136577A3 (fr) Composés antagonistes du récepteur du glucagon, compositions contenant ces composés, et procédés d'utilisation
WO2008070462A3 (fr) N-oxydes d'analogues 4,5-époxy-morphinanium
WO2006104826A3 (fr) Composes antagonistes du recepteur du glucagon, compositions renfermant de tels composes et methodes d'utilisation
WO2006105442A3 (fr) Derives spirocycliques heterocycliques et procedes d'utilisation
WO2007050802A3 (fr) Nouveaux antagonistes opioides
TW200605882A (en) Progesterone receptor modulators comprising pyrrole-oxindole derivatives and uses thereof
WO2008061109A3 (fr) Dérivés d'indazole utiles en tant que ligands des récepteurs de l'hormone concentrant la mélanine
WO2010057118A3 (fr) Antagonistes hétérocycliques des récepteurs de la prostaglandine d2
HK1112916A1 (en) 3-aminocarbazole compounds, pharmaceutical composition containing the same and method for the preparation thereof 3-
EP1844082A4 (fr) Catalyseur metallocene sur support mixte, procede de preparation correspondant, procede de preparation de polyolefine utilisant le catalyseur metallocene sur support mixte et polyolefine preparee a l'aide du procede de preparation de polyolefine utilisant le catalyseur metallocene sur support mixte
EP1814885A4 (fr) Nouveaux composes bicycliques heterocycliques, leur procede de preparation et compositions les contenant
HK1097768A1 (en) Modified pyrimidine glucocorticoid receptor modulators
WO2010077882A3 (fr) Antagonistes des récepteurs d'acide lysophosphatidique
WO2007051062A3 (fr) Dihydropyridines substituees et leurs methodes d'utilisation
WO2006055752A3 (fr) INHIBITEURS DE LA 11-β-HYDROXYSTEROIDE DEHYDROGENASE DE TYPE 1 ET PROCEDES D’UTILISATION
WO2007038669A3 (fr) Composes et compositions contenant de la diarylamine, et utilisation en tant que modulateurs de recepteurs de c-kit
HK1123789A1 (en) Azabicyclic derivatives, preparation method thereof and pharmaceutical compositions containing same
NZ552137A (en) New 4-benzylidene-piperidin derivatives
WO2010039977A3 (fr) Antagonistes d'hétéroaryle des récepteurs de la prostaglandine d2
WO2006119510A3 (fr) Isoformes d'un recepteur pour produits de glycation avancee (rage) et methodes d'identification et d'utilisation de celles-ci
WO2006020680A3 (fr) Composes heterocycliques comme agents pharmaceutiques
TW200800967A (en) Benzimidazole thiophene compounds
WO2009071689A3 (fr) Dérivés d'oxindole substitués par halogène en position 5 et leur utilisation pour traiter des maladies liées à la vasopressine

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 06801924

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 06801924

Country of ref document: EP

Kind code of ref document: A2